Clinical Scorecard: Molecular Profiling, Prognostic Insights, and Immune Landscape Evaluation of NUDT16 in Clear Cell Renal Cell Carcinoma

At a Glance

Key Highlights

• ccRCC accounts for 70-80% of renal cell carcinoma cases.
• Five-year survival rates for localized ccRCC exceed 94%.
• Advanced ccRCC has a five-year survival rate of only 12%.
• NUDT16 is implicated in mRNA degradation and DNA damage repair.
• Emerging studies suggest NUDT16 may serve as a therapeutic target.

Guideline-Based Recommendations

Diagnosis

• Utilize RNA-seq data for expression profiling of NUDT16 in ccRCC.

Management

• Consider NUDT16 expression levels in prognostic assessments and treatment strategies.

Monitoring & Follow-up

• Employ multivariate Cox regression models to evaluate patient outcomes based on NUDT16 expression.

Risks

• Monitor for tumor resistance and disease recurrence in patients with low NUDT16 expression.

Patient & Prescribing Data

Patients diagnosed with clear cell renal cell carcinoma.

Combination therapies involving biologic agents and immune checkpoint inhibitors may improve outcomes.

Clinical Best Practices

• Integrate multi-omics datasets for comprehensive patient assessment.
• Utilize functional experiments to elucidate the role of NUDT16 in ccRCC.
• Assess immune cell infiltration in relation to NUDT16 expression.

References

• The Cancer Genome Atlas
• Gene Expression Omnibus
• R Project
• cBioPortal